Related Experiment Video
Updated: May 13, 2026

High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals
Published on: December 16, 2022
(18)F-FDG PET/CT for the assessment of myocardial sarcoidosis
Hicham Skali1, Allison R Schulman, Sharmila Dorbala
1Department of Radiology, Division of Nuclear Medicine and Molecular imaging, 70 Francis Street, Shapiro 5th Floor, Room 128, Boston, MA 02115, USA.
Insights
Diagnosing cardiac sarcoidosis is challenging. Fluorodeoxyglucose-positron emission tomography (FDG-PET) shows promise for assessing disease activity and guiding treatment in patients with cardiac sarcoidosis.
Area of Science:
- Cardiology
- Nuclear Medicine
- Immunology
Background:
- Cardiac sarcoidosis significantly worsens prognosis.
- Nonspecific symptoms and patchy myocardial involvement complicate early diagnosis.
- A standardized diagnostic approach for cardiac sarcoidosis is lacking.
Purpose of the Study:
- To highlight the utility of imaging modalities for cardiac sarcoidosis.
- To emphasize the role of (18)F-FDG PET in assessing disease activity and treatment response.
- To support the use of (18)F-FDG PET in diagnosis and risk stratification.
Main Methods:
- Review of current literature on cardiac sarcoidosis diagnosis and management.
- Focus on the application and advantages of (18)F-FDG PET imaging.
- Analysis of data supporting (18)F-FDG PET's role in clinical practice.
Main Results:
- Early diagnosis of cardiac sarcoidosis remains difficult due to nonspecific manifestations.
- (18)F-FDG PET offers practical advantages for assessing disease activity.
- (18)F-FDG PET aids in monitoring treatment response and risk stratification.
Conclusions:
- Effective management of cardiac sarcoidosis requires imaging that identifies disease and predicts therapy response.
- (18)F-FDG PET is a valuable tool for diagnosing and managing cardiac sarcoidosis.
- Growing evidence supports the use of (18)F-FDG PET in cardiac sarcoidosis.
Abstract:
Cardiac involvement portends a poor prognosis in patients with sarcoidosis. However, due to the nonspecific clinical manifestations of the disease, patchy myocardial involvement, and the limited diagnostic yield of diagnostic tests, early diagnosis of cardiac sarcoidosis has been exceedingly difficult. As a result, there is no standardized approach for the early diagnosis of cardiac sarcoidosis. Imaging modalities that can both identify disease and predict response to therapy are paramount to improve management of cardiac sarcoidosis. (18)F-FDG PET has many practical advantages in assessing disease activity and monitoring treatment response in patients with cardiac sarcoidosis. Accumulating data support the growing role of (18)F-fluorodeoxyglucose ((18)F-FDG) PET in the diagnosis and risk stratification of patients with cardiac sarcoidosis.
More Related Videos
10:02Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT)
Published on: May 2, 2012
09:5718F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor (SiFA) for Positron Emission Tomography
Published on: January 11, 2020
Related Concept Videos
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...